Tidmarsh announces, then retracts, surrogate endpoint review George Tidmarsh, Director of CDER, posted that while surrogate endpoints have accelerated treatments, they also risk failures in confirmatory trials
As the drugs of the control groups or the background therapies were not specifically defined in some of the included articles, and only one compared the effects of high and normal doses of experimental drugs, we were unable to perform a more detailed subgroup analysis according to them
Bhandari et al., 2017b]
The discovery of these powerful compounds, capable of suppressing appetite and regulating blood sugar, did not begin in a pharmaceutical lab, but with curiosity-driven research and an unlikely source: reptile venom
Those are not the same process
Along with fat loss, some people also lose lean body mass , which includes muscle, water and other tissues